DelveInsight has recently published a report on “Pamrevlumab Market Forecast Report” providing an in-depth analysis of the Pamrevlumab market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The comprehensive report provides an analysis of Pamrevlumab market potential and market share analysis in the Idiopathic Pulmonary Fibrosis therapeutics space across the 7MM from 2019 to 2032.
The report also helps you to understand the Pamrevlumab clinical and commercial developments along with parameters like the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.
Interested in finding out the projected market size of Pamrevlumab by 2032? Visit:Pamrevlumab Market Forecast
Pamrevlumab Drug Summary
FibroGen is in the process of developing pamrevlumab (also referred to as FG-3019), a first-in-class, fully-humanized monoclonal antibody administered intravenously. This innovative antibody effectively inhibits the activity of connective tissue growth factor (CTGF), a pivotal mediator in the progression of fibrosis and associated serious diseases.
Following the successful completion of the Phase II clinical study, FibroGen is now advancing pamrevlumab into Phase III clinical development for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The company is currently conducting two Phase III studies of pamrevlumab in IPF, employing a randomized, double-blind, placebo-controlled design. Each study in the United States has a primary efficacy endpoint focused on the change from baseline in forced vital capacity (FVC). In Europe, the primary efficacy endpoint is defined by disease progression, indicated by a decline in FVC percent predicted of equal to or greater than 10%, or death. Secondary endpoints encompass clinical outcomes related to disease progression, acute IPF exacerbations, patient-reported outcomes, and quantitative changes in lung fibrosis volume from baseline. The enrollment for the ZEPHYRUS-1 trial, the initial Phase III trial involving 356 IPF patients, has been completed. Simultaneously, FibroGen is actively enrolling patients in ZEPHYRUS-2, the second Phase III trial featuring approximately 340 IPF patients.
Beyond IPF, FibroGen is exploring pamrevlumab in Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD) and locally advanced unresectable pancreatic cancer (LAPC). Notably, the drug has shown potential in stabilizing disease and reversing lung fibrosis in certain patients, as reported by the company.
According to FibroGen’s latest updates, the topline data from the ZEPHYRUS-1 Phase III study of pamrevlumab in IPF is anticipated in mid-2023.
Stay ahead of the competition by leveraging key insights and evolving trends in the Pamrevlumab Market @ Pamrevlumab Market Outlook and Key Assessment
Key Highlights of the Pamrevlumab Market Report
Why Pamrevlumab Market Report?
Download the sample report to learn more about the evolving market dynamics @ Pamrevlumab Market Trends and Key Developments
Related Reports By DelveInsight:
Idiopathic Pulmonary Fibrosis Market Outlook and Forecast
“Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology and Market Forecast 2032” report delivers an in-depth understanding of Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan. It also covers the key companies and emerging therapies in the Idiopathic Pulmonary Fibrosis therapeutics landscape.
Top Services Offered By DelveInsight:
Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +91-9650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/case-study/r-and-d-landscape-assessment